Last reviewed · How we verify
Livtencity (MARIBAVIR)
Livtencity works by inhibiting the pUL97 kinase enzyme, which is essential for the replication of cytomegalovirus.
Livtencity (MARIBAVIR) is a small molecule drug developed by Takeda Pharms USA, currently owned by the same company. It is a cytomegalovirus pUL97 kinase inhibitor, approved by the FDA in 2021 for the treatment of post-transplant cytomegalovirus infection. Livtencity is a patented medication with no generic manufacturers available. Key safety considerations include its mechanism of action as a kinase inhibitor, which may have implications for patients with certain medical conditions. It is essential to monitor patients for potential side effects and interactions.
At a glance
| Generic name | MARIBAVIR |
|---|---|
| Sponsor | Takeda |
| Drug class | Cytomegalovirus pUL97 Kinase Inhibitor [EPC] |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
| First approval | 2021 |
| Annual revenue | 300 |
Mechanism of action
LIVTENCITY is an antiviral drug against human CMV [see Microbiology (12.4)].
Approved indications
- Post-transplant cytomegalovirus infection
Common side effects
- Taste disturbance
- Nausea
- Diarrhea
- Vomiting
- Fatigue
- Neutropenia
- Acute kidney injury
- Hemoglobin <6.5 g/dL
- Platelets <25,000 cells/uL
- Creatinine >2.5 mg/dL
- Neutrophils <500 cells/uL
- Hemoglobin >=6.5 to <8.0 g/dL
Key clinical trials
- A Study of Maribavir in Chinese Adults With Cytomegalovirus (CMV) Infections (PHASE3)
- A Study of Maribavir in Adults With Kidney Failure Who Have a Cytomegalovirus (CMV) Infection After Transplantation
- Phase II Trial of Maribavir for CMV in Patients With Lymphoid Malignancy on Bispecific Antibodies (PHASE2)
- A Study of LIVTENCITY (Maribavir) in Adults With Cytomegalovirus (CMV) Infection After Transplantation in South Korea
- A Survey of Maribavir Tablets in Participants With Cytomegalovirus Infection
- Maribavir vs. Valganciclovir for CMV Prophylaxis in High-Risk Kidney Transplant Recipients (PHASE4)
- A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a Single Oral Dose of Maribavir Administered in Healthy Japanese Participants Compared With Matched, Healthy, Non-Hispanic, Caucasian Participants and to Assess Dose-Proportionality of 3 Doses of Maribavir in Japanese Participants (PHASE1)
- A Study of Maribavir in Adults With Post-transplant Cytomegalovirus (CMV) Infection in Belgium
Patents
| Patent | Expiry | Type |
|---|---|---|
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| FDA Orange Book | Patents + exclusivity |
| SEC EDGAR | Revenue + earnings |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Livtencity CI brief — competitive landscape report
- Livtencity updates RSS · CI watch RSS
- Takeda portfolio CI